WARSAW, Ind., Feb. 24, 2011 /PRNewswire/ -- Symmetry Medical Inc. (NYSE: SMA), a leading independent provider of products to the global orthopaedic device industry and other medical markets, announced fourth quarter and full year 2010 financial results for the period ended January 1, 2011.
Fourth Quarter | Total Year | |||||||
(In millions, except per share data) | 2010 | 2009 | Change | 2010 | 2009 | Change | ||
Revenue | $ 96.0 | $ 76.4 | 26% | $ 360.8 | $ 365.9 | -1% | ||
Operating Income | 9.0 | 1.2 | 684% | 28.2 | 36.3 | -22% | ||
Net Income | 4.3 | 0.6 | 674% | 14.0 | 21.8 | -36% | ||
EPS | $ 0.12 | $ 0.02 | 500% | $ 0.39 | $ 0.61 | -36% | ||
Non-GAAP* | ||||||||
Operating Income(1) | 9.1 | 3.1 | 192% | 29.2 | 39.2 | -26% | ||
Net Income(2) | 4.9 | 1.8 | 166% | 15.1 | 23.6 | -36% | ||
EPS(2) | $ 0.14 | $ 0.05 | 180% | $ 0.42 | $ 0.66 | -36% | ||
Revenue by Product | ||||||||
Instruments | $42.3 | $ 32.0 | 32% | $ 145.4 | $ 166.7 | -13% | ||
Implants | 26.2 | 24.8 | 6% | 111.3 | 108.0 | 3% | ||
Cases | 21.6 | 14.8 | 46% | 81.7 | 68.5 | 19% | ||
Other | 5.9 | 4.8 | 23% | 22.4 | 22.7 | -1% | ||
Total Revenue | $ 96.0 | $ 76.4 | 26% | $ 360.8 | $ 365.9 | -1% | ||
* See "Non-GAAP Financial Measures" below. (1) Excludes facility consolidation and severance costs incurred in 2010 and 2009. (2) Excludes facility consolidation and severance costs incurred in 2010 and 2009, as well as debt extinguishment costs incurred in 2010. | ||||||||
Revenue for the fourth quarter 2010 was $96.0 million, up 25.6% compared to $76.4 million in the same period last year and up 4.8% on a sequential basis from $91.5 million in the third quarter 2010. The year-over-year revenue growth reflects improved customer demand in the Company's orthopedic and other medical device businesses. The sequential revenue growth was driven primarily by increased customer demand in the Company's Instruments business and reflects continued stabilization of the Company's Instruments, Implants and Cases businesses in the second half of 2010.
Gross profit for the fourth quarter 2010 was $22.5 million, up 60.9% compared to $14.0 million in the same period last year and up 13.3% compared to $19.8 million in the third quarter 2010. Gross margin percentage for the fourth quarter 2010 was 23.4%, compared to 18.3% in the same period last year and 21.7% for the third quarter 2010. The gross margin expansion was a result of continued manufacturing efficiency improvements coupled with higher sales. This gross margin expansion was partially offset by the Company's continued investment in quality and regulatory services to support increased customer and FDA requirements.
Selling, general and administrative expenses in the fourth quarter 2010 were $13.4 million, compared to $10.9 million in the same period last year and $12.2 million in the third quarter 2010. The increase in selling, general and administrative expenses in the fourth quarter 2010 was primarily related to increased research and development expenses, direct sales activities at the SSI distribution unit, increased healthcare expense, as well as an increase in sales commissions related to higher revenue. Facility closure and severance costs were negligible in the fourth quarter of 2010, compared to $2.0 million in the same period last year and $0.1 million in the third quarter of 2010.
Operating income for the fourth quarter 2010 was $9.0 million, up 683.7% compared to $1.2 million in the same period last year and up 19.9% compared to $7.5 million in the third quarter 2010. Operating margin for the fourth quarter 2010 was 9.4%, compared to 1.5% in the same period last year and 8.2% in the third quarter 2010. Excluding expenses related to facility consolidation and employee severance payments referenced above, operating income for the fourth quarter 2010 was $9.1 million, compared to $3.1 million in the same period last year and $7.6 million in the third quarter 2010.
The fourth quarter 2010 results include a debt extinguishment charge of $0.8 million pre-tax, or $0.5 million after tax, related to the Company's debt refinancing activities completed during the fourth quarter of 2010.
The fourth quarter 2010 included a non-cash gain of $0.2 million for the mark to market of the Company's interest rate derivative, compared to a non-cash gain for the interest rate derivative of $0.4 million in the fourth quarter 2009. All existing interest rate derivative instruments were unwound during November 2010 in connection with the Company's debt refinancing activities.
Income tax expense for the fourth quarter 2010 was $2.6 million, compared to an income tax benefit of $0.6 million for the fourth quarter of 2009. The fourth quarter 2010 effective tax rate of 38% was higher than the Company's expectations and full year 2010 rate of 36% due primarily to the unfavorable impacts of foreign taxes, which more than offset the favorable impact of the $0.3 million benefit from the Federal Research and Development tax credit, extended by the Federal Government in the fourth quarter of 2010.
Net income for the fourth quarter 2010 was $4.3 million, or $0.12 per diluted share, compared to $0.6 million, or $0.02 per diluted share, in the same period last year and $3.6 million, or $0.10 per diluted share, in the third quarter of 2010. Excluding the facility consolidation, employee severance payments and debt extinguishment charges referenced above, net income for the fourth quarter 2010 was $4.9 million, or $0.14 per diluted share, compared to $0.05 in the same period last year and $0.10 in the third quarter 2010.
The weighted average number of diluted shares outstanding during the fourth quarter of 2010 was 35,835,916.
Revenue for the full year 2010 was $360.8 million, compared to $365.9 million reported in the full year 2009. Gross margin percentage for the full year 2010 was 22.1%, compared to 23.8% for the full year 2009. Net income for the full year 2010 was $14.0 million, or $0.39 per diluted share, compared to $21.8 million, or $0.61 per diluted share, reported in the full year 2009. Excluding the facility consolidation, employee severance payments and debt extinguishment charge referenced above, net income for the full year 2010 was $15.1 million, or $0.42 per diluted share, compared to $23.6 million, or $0.66 per diluted share, reported in the full year 2009.
Thomas J. Sullivan, President and Chief Executive Officer of Symmetry Medical, stated, "Symmetry ended the year with our fourth consecutive quarter of sequential revenue growth driven by our core orthopedic and other medical device businesses, giving us confidence that the challenging market conditions which impacted our results in the second half of 2009 and into the first half of 2010 have abated. We were pleased to achieve robust revenue growth in our instrument business over the third quarter and stable volumes across the rest of our business. This revenue growth, combined with increased efficiencies, resulted in improved margins in the quarter despite the ongoing spending in response to increased quality and regulatory requirements. While these investments impact our bottom line results, over time we believe they will provide further differentiation as our customers continue to consolidate their demand with trusted strategic providers."
"In my first month as Symmetry's Chief Executive Officer I have had the opportunity to see firsthand the Company's manufacturing plants and to hear directly from our customers about the superior level of quality products and service that Symmetry is known for in the industry. I believe that the strength of our brand equity, coupled with our quality and regulatory leadership, the depth and breadth of our technologies and our worldwide facilities and sales force, enable a strong foundation for growth. In the months ahead we will develop a plan to further enhance profitability, as well as identify expansion opportunities where we can build upon our strengths or find attractive acquisitions to add to the Symmetry family which will bring additional services and or manufacturing competencies that will be attractive to customers as part of our Total Solutions offering."
Fred L. Hite, Senior Vice President and Chief Financial Officer of Symmetry Medical, remarked, "In 2011, we anticipate that our revenue will grow in-line to slightly faster than the core orthopedic market, driven by market share gains and the increased diversification of our business. On the bottom line, we expect significant EPS expansion as we continue to improve margins throughout the year."
Financial Guidance
The following forward-looking estimates regarding 2011 guidance reflect current market conditions and foreign currency rates. Actual results may differ materially, and the Company refers you to forward-looking statements located at the end of the press release.
For the full year 2011, the Company expects revenue to be in the range of $363 million to $383 million. The Company expects full year 2011 GAAP earnings per diluted share to be in the range of $0.50 to $0.58 and full year 2011 non-GAAP earnings per diluted share to be in the range of $0.57 to $0.65. The non-GAAP earnings per diluted share guidance excludes the impact of management transition expenses which are expected to negatively impact full year 2011 GAAP earnings per diluted share by approximately $0.07.
Conference Call
Symmetry Medical will host a conference call to discuss fourth quarter and full year 2010 financial results at 8:00 a.m. ET on February 24, 2011.A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate Web site at www.symmetrymedical.com. The dial-in numbers are (800) 573-4840 for domestic callers and (617) 224-4326 for international. The reservation number for both is 65718196.After the live Web cast, the call will remain available on Symmetry Medical's Web site through May 24, 2011. In addition, a telephonic replay of the call will be available until March 10, 2011. The replay numbers are (888) 286-8010for domestic callers and (617) 801-6888for international callers. Please use reservation code 64799370.
About Symmetry Medical Inc.
Symmetry Medical Inc. is a leading independent provider of implants and related instruments and cases to the orthopaedic device industry. The Company also designs, develops and produces these products for companies in other segments of the medical device market, including arthroscopy, dental, laparoscopy, osteobiologic and endoscopy sectors and provides limited specialized products and services to non-healthcare markets, such as the aerospace market.
Non-GAAP Measures
The non-GAAP measures, including adjusted operating income, net income and EPS, shown in this release exclude facility consolidation, severance costs, and debt extinguishment charges. Re
